Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results